川宁生物 - Financials

川宁生物 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018
+Revenue	5.8B	4.8B	3.8B	3.2B	3.6B	3.1B	3.3B
Revenue Growth %	19.4%	26.2%	18.2%	-11.4%	16.1%	-6.2%	--
Total Revenue	5.8B	4.8B	3.8B	3.2B	3.6B	3.1B	3.3B
Cost Of Revenue	3.7B	3.3B	2.9B	2.5B	2.9B	2.5B	2.5B
+Gross Profit	2.1B	1.5B	948.0M	718.0M	787.0M	667.0M	837.0M
Gross Margin %	36.4%	31.6%	24.8%	22.2%	21.6%	21.2%	25.0%
Total Operating Cost	4.1B	3.7B	3.3B	3.0B	3.4B	3.0B	3.0B
Selling Expenses	25.5M	22.6M	11.5M	9.8M	15.6M	56.0M	44.5M
Admin Expenses	165.0M	143.0M	144.0M	231.0M	247.0M	214.0M	178.0M
Rd Expenses	77.7M	55.3M	35.4M	33.0M	25.0M	18.2M	4.7M
Finance Expenses	48.4M	60.8M	123.0M	178.0M	181.0M	186.0M	190.0M
+Operating Income	1.7B	1.1B	545.0M	224.0M	279.0M	117.0M	393.0M
Operating Margin %	29.3%	23.2%	14.3%	6.9%	7.6%	3.7%	11.7%
Non Operating Income	1.1M	2.0M	34,400	428,200	67,800	440,700	500.00
Non Operating Expenses	13.8M	5.7M	57.5M	90.0M	2.6M	7.5M	3.1M
Investment Income	-9.2M	-13.6M	-8.9M	3.3M	1.7M	--	--
Fair Value Change Income	31,500	-1.2M	-58,100	548,200	421,100	--	--
Asset Disposal Income	--	1.3M	--	261,100	--	--	--
Asset Impairment Loss	17.1M	42.7M	16.6M	12.6M	5.9M	2.0M	8.9M
Other Income	8.8M	9.4M	6.3M	3.8M	9.9M	6.0M	4.9M
Income Before Tax	1.7B	1.1B	488.0M	134.0M	276.0M	110.0M	390.0M
Income Tax	275.0M	177.0M	76.1M	22.7M	47.1M	20.0M	-837,600
+Net Income	1.4B	941.0M	412.0M	111.0M	229.0M	90.2M	391.0M
Net Margin %	24.3%	19.5%	10.8%	3.4%	6.3%	2.9%	11.7%
Net Income Attributable	1.4B	941.0M	412.0M	111.0M	229.0M	91.4M	390.0M
Minority Interest	26,100	1,000	-700.00	400.00	2,000	-1.2M	933,100
Eps Basic	0.63	0.42	0.21	0.06	0.11	0.02	0.10
Eps Diluted	0.63	0.42	0.21	0.06	0.11	--	--

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018
Cash And Equivalents	1.1B	761.0M	1.6B	510.0M	510.0M	174.0M	148.0M
Trading Financial Assets	--	--	1.2M	1.2M	421,100	--	--
Accounts Receivable	939.0M	748.0M	878.0M	781.0M	830.0M	1.2B	855.0M
Notes Receivable	--	--	--	--	--	--	212.0M
Notes And Accounts Receivable	939.0M	748.0M	878.0M	781.0M	830.0M	1.2B	1.1B
Prepayments	89.1M	44.9M	85.0M	61.5M	95.2M	107.0M	301.0M
Inventory	1.3B	1.7B	1.4B	1.5B	1.4B	1.4B	1.0B
Total Current Assets	4.1B	4.0B	4.5B	3.2B	3.3B	3.1B	2.6B
Long Term Equity Investment	15.8M	6.8M	6.9M	--	--	--	--
Fixed Assets	--	5.1B	5.5B	5.8B	5.9B	6.0B	6.1B
Fixed Assets Total	5.3B	5.1B	5.5B	5.8B	5.9B	6.0B	6.1B
Construction In Progress	--	538.0M	60.1M	96.4M	356.0M	384.0M	473.0M
Construction In Progress Total	285.0M	538.0M	60.1M	96.4M	356.0M	384.0M	473.0M
Intangible Assets	236.0M	258.0M	283.0M	272.0M	212.0M	230.0M	191.0M
Long Term Deferred Expenses	1.5M	2.4M	3.4M	4.7M	982,900	--	--
Total Non Current Assets	6.4B	6.2B	5.9B	6.2B	6.6B	6.8B	6.9B
Total Assets	10.6B	10.1B	10.4B	9.5B	9.9B	9.9B	9.5B
Short Term Borrowings	210.0M	851.0M	979.0M	700.0M	791.0M	401.0M	--
Accounts Payable	745.0M	717.0M	631.0M	671.0M	678.0M	646.0M	578.0M
Advance Receipts	--	--	--	--	--	6.5M	7.0M
Contract Liabilities	66.8M	28.9M	38.0M	21.3M	15.8M	--	--
Total Current Liabilities	1.9B	2.5B	2.7B	2.6B	2.4B	5.5B	5.1B
Long Term Borrowings	146.0M	357.0M	1.4B	2.1B	2.8B	--	--
Total Non Current Liabilities	690.0M	630.0M	1.5B	2.1B	2.9B	7.9M	10.0M
Total Liabilities	2.6B	3.2B	4.2B	4.7B	5.3B	5.5B	5.1B
Paid In Capital	2.2B	2.2B	2.2B	2.0B	2.0B	4.0B	4.0B
Capital Reserve	3.3B	3.3B	3.2B	2.4B	2.4B	410.0M	410.0M
Surplus Reserve	325.0M	172.0M	74.0M	34.0M	22.9M	2.0M	--
Retained Earnings	2.1B	1.3B	678.0M	307.0M	206.0M	18.8M	-60.3M
Minority Equity	18.8M	12.9M	6.0M	6.0M	6.0M	--	16.9M
Equity Attributable	7.9B	7.0B	6.2B	4.8B	4.7B	4.4B	4.3B
Total Equity	7.9B	7.0B	6.2B	4.8B	4.7B	4.4B	4.4B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018
Cash From Sales	4.7B	4.0B	2.9B	2.6B	2.5B	1.6B	2.0B
Tax Refunds Received	20.7M	8.9M	251,100	34.7M	29.9M	57.9M	81.9M
Total Operating Cash Inflow	4.8B	4.2B	2.9B	2.7B	2.5B	1.7B	2.1B
Cash Paid For Goods	1.7B	1.8B	1.5B	1.4B	1.3B	1.3B	1.4B
Cash Paid To Employees	487.0M	417.0M	349.0M	300.0M	301.0M	309.0M	276.0M
Taxes Paid	669.0M	538.0M	284.0M	169.0M	204.0M	128.0M	24.0M
Total Operating Cash Outflow	3.0B	2.9B	2.2B	1.9B	1.9B	1.8B	1.8B
Operating Cash Flow	1.8B	1.3B	692.0M	803.0M	650.0M	-147.0M	310.0M
Total Investing Cash Inflow	206.0M	202.0M	0.00	4.1M	1.7M	--	7.9M
Total Investing Cash Outflow	312.0M	555.0M	54.2M	52.3M	89.2M	65.4M	29.5M
Investing Cash Flow	-106.0M	-353.0M	-54.2M	-48.2M	-87.5M	-65.4M	-21.5M
Cash From Borrowings	780.0M	852.0M	1.2B	933.0M	4.3B	400.0M	--
Dividends And Interest Paid	545.0M	290.0M	143.0M	168.0M	57.3M	1.0M	--
Debt Repayments	1.6B	2.4B	1.6B	1.5B	400.0M	--	--
Total Financing Cash Inflow	806.0M	859.0M	2.2B	933.0M	4.3B	939.0M	1.0B
Total Financing Cash Outflow	2.2B	2.7B	1.7B	1.7B	4.5B	705.0M	1.2B
Financing Cash Flow	-1.4B	-1.8B	476.0M	-749.0M	-219.0M	234.0M	-177.0M
Net Change In Cash	330.0M	-866.0M	1.1B	-759,300	339.0M	23.3M	118.0M
Ending Cash Balance	1.1B	758.0M	1.6B	507.0M	507.0M	169.0M	146.0M
Capex	42.6M	345.0M	47.2M	52.3M	89.2M	65.4M	29.5M